Radi Zaher A, Render James A
Drug Safety Research and Development, Pfizer Global Research and Development, Chesterfield, MO 63017, USA.
J Ocul Pharmacol Ther. 2008 Apr;24(2):141-51. doi: 10.1089/jop.2007.0078.
Cyclooxygenase isoenzymes (COX-1 and -2) catalyze the conversion of arachidonic acid to prostaglandins (PGs) and play a significant role in the health and disease of the eye. Experimental animal models of ocular diseases have been used to assess the effects of the selective COX inhibitors (COXIBs), and nonselective, nonsteroidal anti-inflammatory drugs (ns-NSAIDs) are currently employed in the management of various ophthalmic conditions. This paper provides a review of the comparative expression of COX-1 and COX-2 in the eye under normal and pathologic conditions, including the pathophysiologic role of PGs, and the effects of ns-NSAIDs and selective COX-2 inhibitors in the treatment of ophthalmic conditions.
环氧化酶同工酶（COX-1和COX-2）催化花生四烯酸转化为前列腺素（PGs），并在眼部健康和疾病中发挥重要作用。眼部疾病的实验动物模型已被用于评估选择性COX抑制剂（COXIBs）的效果，目前非选择性非甾体抗炎药（ns-NSAIDs）被用于治疗各种眼科疾病。本文综述了正常和病理条件下眼部COX-1和COX-2的比较表达，包括PGs的病理生理作用，以及ns-NSAIDs和选择性COX-2抑制剂在治疗眼科疾病中的作用。
